Although multiple factors undoubtedly contribute, extensive evidence indicates that vascular dysfunction plays a pathogenic role in depression-CVD comorbidity. MDD is associated with impairments in vascular function graded in relation to the severity of depressive symptoms. [8] [9] [10] [11] Depression-induced impairments in brachial artery endothelium-dependent dilation (flow-mediated dilation) are indicative of reductions in vascular NO bioavailability and function. 8, [11] [12] [13] [14] These functional vascular measures are consistent with the generalized reductions in plasma NO metabolite concentration reported in MDD. 15, 16 Original received July 19, 2018; revision received December 5, 2018; accepted December 10, 2018. In November 2018 Rationale: In rodent models of depression, oxidative stress-induced reductions in NO bioavailability contribute to impaired endothelium-dependent dilation. Endothelial dysfunction is evident in major depressive disorder (MDD); however, the molecular mediators remain undefined.
D epression, defined as either major depressive disorder (MDD) or significant depressive symptoms with substantial functional impairment, 1 occurs in ≈10% to 15% of the population 2 and is projected to become the second leading cause of worldwide disease and disability by 2030.
However, the specific mechanisms underlying reductions in NO-mediated endothelial function in MDD remain relatively undefined. In rodent models of depression, [17] [18] [19] the deficit in endothelial function is due, in part, to increased vascular oxidative stress, specifically superoxide, and subsequent attenuation of NO-dependent dilation. In depressed adults, biomarkers of oxidative stress (eg, plasma lipid peroxidation, platelet protein carbonylation) are increased. 20, 21 However, no studies have directly examined NO-mediated vascular function in vivo in MDD using targeted pharmacological approaches, nor have any studies investigated the potential sources of, or a role for, oxidative stress in mediating endothelial dysfunction in otherwise healthy adults with depression.
The link between depression and CVD may be modulated by sex. Compared with age-matched men, premenopausal women have lower CVD risk, 22 yet are more than twice as likely to experience depressive disorders. 23 However, epidemiological data also suggest that MDD is associated with a greater CVD incidence in women compared with men. 6, 24 These apparently contradictory notions implicate potential sex differences in the pathophysiological mechanisms underlying MDD-CVD comorbidity. In this regard, female rodents display increased behavioral susceptibility to depression, but less severe impairments in endothelial function compared with their male counterparts, 17, 19 owing to greater antioxidant defense mechanisms. 17, 19, 25 Despite this compelling preclinical evidence, to our knowledge, no investigations have examined potential sex differences in the mechanistic underpinnings of endothelial dysfunction in human MDD. Such studies are critical to develop sex-specific preventative and therapeutic interventions.
The aim of the present investigation was to directly examine the mechanisms mediating microvascular endothelial dysfunction, including the modulatory influence of sex, in treatment-naive, otherwise healthy, young adults with MDD compared with healthy, nondepressed men and women (healthy control [HC] ). We systematically examined endothelium-dependent dilation, vascular smooth muscle sensitivity, and the effect of acute pharmacological inhibition of oxidative stress on endothelial function in the cutaneous microcirculation-a validated bioassay for systemic microvascular function. [26] [27] [28] [29] [30] Complementary to our direct pharmacological assessment of the molecular mediators of microvascular function, we performed ex vivo analyses of endothelium-dependent signaling pathways and oxidative stress-related enzyme abundance/expression and activity in cutaneous tissue homogenates obtained from MDD and HC adults. We hypothesized that MDD adults would have (1) attenuated endothelium-dependent dilation, (2) 
Novelty and Significance
What Is Known?
• In rodent models of depression, increased vascular oxidative stress, specifically superoxide production and subsequent reductions in NO bioavailability mediate endothelial dysfunction.
• Because of increased antioxidant defense mechanisms and a relative preservation of NO bioavailability, depression-induced impairments in endothelium-dependent dilation are less severe in female rodents.
• Although endothelial dysfunction is evident in adult humans with major depressive disorder (MDD), the molecular mediators remain undefined.
What New Information Does This Article Contribute?
• In both men and women with MDD with mild-to-moderate symptomology, reductions in NO-dependent mechanisms contribute to impaired endothelium-dependent dilation; however, there are no sex differences in NO-dependent dilation in MDD.
• Acute scavenging of superoxide or inhibition of NADPH oxidase improves the NO-mediated component of endothelium-dependent dilation in MDD adults, suggesting that increased vascular oxidative stress, specifically increased superoxide, contributes to microvascular dysfunction in MDD.
Depressive disorders have been linked to the excessive and premature development of cardiovascular disease. Vascular endothelial dysfunction appears to play a pathogenic role in depression-cardiovascular disease comorbidity; however, the molecular mediators remain undefined. Based on evidence in rodent models of depression indicating a causal role for increased oxidative stress, we examined the role of superoxide in mediating microvascular endothelial dysfunction in treatment-naive, otherwise healthy, young adults with MDD. In comparison with healthy nondepressed adults, NO-mediated endothelium-dependent dilation was attenuated in adults with MDD. Endothelium-independent dilation was also blunted. Nevertheless, there were no differences in microvascular function between men and women with MDD. [31] [32] [33] and in an effort to gain preliminary insight to the relation between depressive symptoms and microvascular dysfunction, we also examined endothelium-dependent and endothelium-independent dilation in a subset of adults with MDD treated with an SSRI for their depression and in remission.
Methods
A detailed Methods and Materials section is available in the Online Data Supplement. All experimental procedures and protocols were approved by the Institutional Review Board at the Pennsylvania State University. The investigation was conducted in accordance with the Declaration of Helsinki. The nature, risks, and benefits of all study procedures were explained to volunteers, and their verbal and written informed consent was obtained voluntarily before participation.
A total of 44 participants were tested: 20 healthy adults (10 men) without any history of major psychiatric illness and 24 otherwise healthy MDD patients (10 men) with a current symptomatic major depressive episode (nonmedicated; Online Table I ). Additionally, 8 adults diagnosed with MDD and currently treated with an SSRI for their depressive symptoms (monotherapy) were also tested (Online Table II ). All SSRI-treated adults were treated for at least 8 weeks before study enrollment, and their MDD was in remission, confirmed by the absence of clinically meaningful depressive symptoms.
Assessment of Microvascular Function (In Vivo)
Using sterile technique, intradermal microdialysis probes (CMA Linear 30 probe, 6 kDa; Harvard Apparatus, Holliston, MA) were inserted into the dermal layers of the ventral forearm for the local delivery of pharmacological agents, as described previously. 34 Red blood cell flux-an index of cutaneous blood flow-was continuously measured directly over each microdialysis site with an integrated laser Doppler flowmeter probe placed in a local heating unit (VP12 and VHP2; Moor Instruments, Wilmington, DE) set to thermoneutrality (33°C), unless noted otherwise. Automated brachial blood pressure (Cardiocap; GE Healthcare, Milwaukee, WI) was measured every 5 minutes.
Endothelium-dependent dilation was assessed by perfusion of ascending concentrations of acetylcholine (ACh; 10 −10 -10 −1 mol/L; United States Pharmacopeia, Rockville, MD) alone and during concurrent administration of 15 mmol/L N G -nitro-L-arginine methyl ester (L-NAME; Calbiochem, EMD Millipore, Billerica, MA) to nonselectively inhibit NO synthase (NOS), 10 µmol/L 4-HydroxyTempo (Tempol; Sigma-Aldrich, St. Louis, MO) to scavenge superoxide, 100 µmol/L apocynin (Bio-Techne Corporation, Minneapolis, MN) to inhibit NADPH oxidase, Tempol+L-NAME, or apocynin+L-NAME. [34] [35] [36] [37] [38] Endothelium-independent dilation was assessed by perfusion of ascending concentrations of sodium nitroprusside (SNP; 10 −7 -10 −1 mol/L; United States Pharmacopeia). Following each doseresponse protocol, maximal dilation was elicited. 34, 39 Details are provided in the Online Data Supplement.
Assessment of Expression and Activity of NO and Oxidative Stress (In Vitro)
In a subset of participants (n=8 HC, n=8 MDD), two 3-mm cutaneous vascular tissue samples were obtained from the ventral forearm under local anesthesia (2% lidocaine without epinephrine) via punch biopsy, immediately snap-frozen in liquid nitrogen, and stored at −80°C until analysis. 34, 40 Protein abundance/expression was determined by Western blot and total reactive oxygen species and reactive nitrogen species (ROS+RNS) production was quantified fluorometrically (Cell Biolabs Inc, San Diego, CA). The relative contribution of superoxide to total ROS+RNS was assessed by pretreatment with the SOD (superoxide dismutase) mimetic MnTBAP (Sigma-Aldrich). Details are provided in the Online Data Supplement.
Data and Statistical Analysis
Data were recorded at 40 Hz (PowerLab and LabChart; ADInstruments, Bella Vista, NSW, Australia). Vascular conductance was calculated as laser Doppler flux (perfusion units) divided by mean arterial pressure, normalized as a percentage of the site-specific maximum (%CVC max ), and averaged during 5 minutes of baseline and during the last minute of each ACh or SNP dose. The NO-mediated component of ACh-induced dilation was calculated as the difference between control/Tempol/apocynin and the corresponding L-NAMEtreated site (arbitrary units). 34, 40 Student unpaired t tests were used to compare subject characteristics and biochemical data. Sigmoidal dose-response curves with variable slope were generated using nonlinear regression modeling (Prism; GraphPad, San Diego, CA). Differences between groups and microdialysis sites in the logEC 50 (effective concentration resulting in 50% of the maximal response) were analyzed using a Fisher test for repeated-measures comparisons. 40, 41 NO-dependent dilation was analyzed using 2-way (group x. pharmacological agent) mixed-model repeated-measures ANOVA, with post hoc Bonferroni corrections applied for specific planned comparisons (SAS v9.4; Cary, NC). If necessary, these statistical analyses were also performed separately with the inclusion of the SSRI-treated group. Values are presented as mean±SEM, and significance was set at α <0.05.
Results

Participant Characteristics
Participants in the HC and MDD groups were well matched for anthropometric characteristics, habitual physical activity, resting hemodynamics, and blood biochemistry (all P>0.05), although MDD adults were significantly younger than HC (Online Table I ; P=0.01). Adults with MDD were experiencing a major depressive episode of mild-moderate severity (Online Table I ; P<0.01).
NO-Mediated Endothelium-Dependent and Endothelium-Independent Dilation Are Blunted in MDD
Neither baseline nor SNP-induced maximal vascular conductance was different between groups or pharmacological treatments (Online Table III 
Sex Does Not Modulate NO-Dependent Microvascular Endothelial Function in MDD
There were no differences in ACh-induced vasodilation between HC men and women (Online Figure IIIA; 
Oxidative Stress Mediates Attenuated NODependent Endothelial Function in MDD
As expected, because increased vascular oxidative stress is not evident in healthy young adults, perfusion of Tempol ( Figure 3A and 3C) or apocynin ( Figure 3D and 3F) had no effect on ACh-induced vasodilation in HC (−6.4±0. 50 ; P=0.32) on microvascular sensitivity to ACh was not statistically significant ( Figure 3B and 3E) . However, there were also no differences in endothelium-dependent dilation during NOS inhibition in the presence or absence of either Tempol ( Figure 3B ; −4.7±0.6 L-NAME versus −4.1±0.4 Tempol+L-NAME logEC 50 ; P=0.08) or apocynin ( Figure 3E ; −4.7±0.6 L-NAME versus −3.9±0.4 apocynin+L-NAME logEC 50 
NO-Mediated Endothelium-Dependent Dilation Is Not Impaired in SSRI-Treated Adults With MDD
SSRI-treated adults were not currently experiencing a major depressive episode (Online Table II 
Discussion
This is the first study in humans to directly assess the contribution of superoxide to impaired NO-mediated microvascular function in MDD using a targeted in vivo pharmacological approach. The present findings demonstrate significantly attenuated endothelium-dependent dilation in MDD adults with mild-moderate symptomology that is mediated, in part, by reductions in NO-dependent mechanisms. Endotheliumindependent dilation was also blunted in MDD, suggesting that alterations in VSMC sensitivity to NO also contribute to microvascular dysfunction. However, contrary to our initial hypothesis, there were no sex differences in either NO-mediated endothelium-dependent dilation or endothelium-independent dilation in MDD. Further, in MDD, acute administration of either a superoxide scavenger or an NADPH oxidase inhibitor improved NO-dependent dilation. Taken together with the ex vivo biochemical analyses demonstrating increased abundance/expression and activity of enzymes associated with an increased oxidative load, these data support the hypothesis that increased vascular oxidative stress contributes to microvascular dysfunction in MDD. Finally, NO-mediated endothelium-dependent dilation was preserved, but endothelium-independent dilation was impaired, in SSRI-treated adults with MDD in remission. Collectively, these findings provide support for the concept that ROS-induced reductions in NOdependent mechanisms directly contribute to microvascular dysfunction in MDD and further suggest that targeting oxidative stress, specifically superoxide, may be a viable therapeutic strategy for improving vascular function and reducing CVD risk in adults with depression.
In rodent models, the development of a depressive phenotype is causally linked to impairments in endothelium-dependent dilation in both the conduit and resistance vasculature. [17] [18] [19] [42] [43] [44] These functional deficits are specific to the endothelium because dilation in response to exogenous NO and adrenergic vasoconstriction is not different from that in HC rodents. 18, 19, 42, 44 Mechanistically, blunted endotheliumdependent dilation is mediated in large part by impairments in NO bioavailability and function. [17] [18] [19] [42] [43] [44] Extensive preclinical evidence further suggests that excessive superoxide production contributes to depression-induced endothelial dysfunction. [17] [18] [19] 45, 46 Further, treatment of aortic segments isolated from depressed rodents with a superoxide scavenger improves endothelium-dependent dilation via increases in vascular NO production. 17, 19, 45 These data suggest that increased ROS generation, specifically superoxide, directly limits NO bioavailability and mechanistically contributes to endothelial dysfunction in rodent models of depression.
Few studies have examined vascular function in otherwise healthy young adults with MDD and free of any other cardiovascular risk factors. Of these, the majority have reported depression-induced deficits in gross measures of endothelial function, 8, [11] [12] [13] [14] although this is not a universal finding. 16 Most studies have assessed endothelial function utilizing a reactive hyperemia-induced increase in endothelial shear stress, typically via brachial artery flow-mediated dilation. Although NO mediates ≈50% of conduit artery flow-mediated dilation in young, healthy individuals, 47 making it a valid measure of endothelium-dependent vasomotor function in the human macrovasculature, the technique does not allow for the direct quantification of NO-dependent dilation nor does it permit investigation of the specific mechanisms mediating endothelial dysfunction. We used the human cutaneous circulation to probe the mechanisms mediating microvascular dysfunction in MDD. The cutaneous circulation is a validated model for generalized microvascular function and has been used to examine the mechanisms underlying microvascular dysfunction in multiple pathologies. [26] [27] [28] [29] [30] Moreover, disease-related alterations in microvascular function often first appear in the February 15, 2019 cutaneous circulation, making it an accessible circulatory bed in which to examine mechanistic alterations in vascular function as a means for the early identification of patients at risk for the future development of CVD, before overt target-organ damage becomes apparent. 29 Using this model, and consistent with reports of large artery dysfunction in depression, the present findings demonstrate marked impairments in microvascular ACh-induced dilation in MDD. Nonselective pharmacological inhibition of NOS attenuated ACh-induced dilation in HC, but not in MDD, indicating that a functional absence of NO-mediated dilation contributes to endothelial dysfunction in MDD. To further examine potential MDD-induced reductions in NO bioavailability, we measured expression of eNOS and phosphorylated eNOS in cutaneous tissue homogenates. We did not detect a reduction in phosphorylated eNOS in MDD. Although perhaps surprising, these ex vivo data are consistent with reports of unaltered eNOS expression in rodent models of depression. 18 Therefore, although the use of a nonselective NOS inhibitor precludes conclusions regarding the isoform-specific source of NO in the vasculature, we nevertheless interpret these data as suggesting that vascular NO production per se is not reduced in MDD. Instead, it appears likely that mechanisms secondary to NO production and diffusion modulate endothelial dysfunction in MDD.
In this regard, excessive superoxide rapidly oxidizes and inactivates NO. 48 Thus, building on preclinical data, [17] [18] [19] 45, 46 we sought to elucidate whether increased vascular superoxide directly contributes to blunted NO-dependent dilation in human MDD. Acute localized treatment with Tempol-a scavenger of superoxide anion 49 -improved NO-mediated dilation in MDD. These data suggest that vascular superoxide mechanistically contributes to endothelial dysfunction in MDD. However, Tempol is not specific for superoxide and has been shown to metabolize other ROS (eg, hydrogen peroxide, hydroxyl radicals, and peroxynitrite). 37 To circumvent this issue, we also assessed endothelial function after acute administration of apocynin to inhibit NADPH oxidase 38 -a major source of superoxide in the endothelium. 50 Similar to Tempol, treatment with apocynin improved NO-mediated endothelium-dependent dilation. Interestingly, the improvements in endothelial function after acute antioxidant treatment were only evident for NO-mediated dilation because neither Tempol nor apocynin alone directly improved endothelial sensitivity to ACh. The reason(s) underlying this seemingly paradoxical finding is not immediately clear. Nevertheless, these data suggest that increased vascular ROS production, specifically -nitroarginine methyl ester [L-NAME]; B) in a subset of adults with major depressive disorder who were treated with a selective serotonin reuptake inhibitor and in remission (MDD+SSRI; n=8). ACh-induced dilation in healthy adults (HC) and untreated adults with MDD is presented for reference. Endothelium-dependent dilation in SSRI-treated adults was not different from that in HC, because of a relative preservation of NO-mediated dilation. SSRI indicates selective serotonin reuptake inhibitors. Figure 8 . Vascular conductance in response to increasing doses of sodium nitroprusside (SNP) in a subset of adults with major depressive disorder who were treated with a selective serotonin reuptake inhibitor and in remission (MDD+SSRI; n=8). SNP-induced dilation in healthy adults (HC) and untreated adults with MDD is presented for reference. Endothelium-independent dilation was attenuated in SSRItreated adults. Data are mean±SE. *P<0.05 vs HC. SSRI indicates selective serotonin reuptake inhibitors.
NADPH oxidase-derived superoxide, directly contributes to impairments in NO-mediated signaling mechanisms and subsequent endothelial dysfunction in human depression.
Consistent with our functional data indicating a role for excessive microvascular superoxide production, increased circulating markers of oxidative stress and decreased antioxidant markers have been reported in MDD. 20, 21, 51, 52 We did not detect MDD-related elevations in plasma oxidized LDL (low-density lipoprotein)-a generalized biomarker of systemic oxidative damage to lipids. 53 Because ROS have a short half-life, there is inherent difficulty in making gross measurements, and these are not necessarily reflective of tissue concentrations. In addition, there is a wide range of oxidative stress biomarkers, the type of biological specimen used, and laboratory techniques for measurement, each with its own strengths and limitations. However, to complement the measure of whole-body redox control, we also measured tissue-specific expression of oxidant and antioxidant enzymes, as well as total ROS+RNS production. Consistent with previous findings, 21 nitrotyrosine abundance and expression of the p47 phox subunit of NADPH oxidase were increased in cutaneous tissue homogenates from MDD. Further, total ROS+RNS activity and superoxide generation specifically were markedly increased in MDD. We additionally expected to demonstrate a reduction in SOD expression in MDD. There were no group differences in expression of the antioxidant enzymes SOD1 and SOD2. These data, however, do not rule out potential deficits in SOD activity or post-translational modifications. Regardless, it appears that superoxide production in MDD outstrips the ability of SOD to handle the oxidative load, especially in the absence of a compensatory upregulation in antioxidant defense mechanisms. We acknowledge that the cutaneous tissue homogenates represent mixed tissue (blood vessels, keratinocytes, nerve endings, etc) and provide limited ability to specifically assess protein expression/activity in endothelial or VSMC alone. Nevertheless, when considered collectively with the functional in vivo data, the present findings build on and extend those from preclinical models and strongly suggest that increased NADPH oxidase-derived superoxide directly contributes to MDD-induced microvascular endothelial dysfunction via reductions in NO-mediated mechanisms.
Unexpectedly, expression of pVASP, which is reflective of downstream eNOS-cGMP signaling in the VSMC, 54 was not reduced in cutaneous tissue homogenates from MDD patients. This finding may appear incongruous with the functional data because it suggests that the primary mechanism contributing to reductions in NO-dependent dilation in MDD was not eNOS uncoupling. However, there are other downstream mechanisms by which superoxide may influence VSMC function. As such, our interpretation of these data is that superoxide is likely exerting both NO-dependent and NO-independent effects. Indeed, vascular oxidative stress has been linked to impairments in cGMP-dependent protein kinase activity in VSMCs themselves, leading to attenuated relaxation. 54 Thus, it is feasible that the persistent and elevated superoxide generation in MDD directly impairs dilator mechanisms and concurrently activates myogenic constrictor pathways within VSMCs, 55 independent of NO, thus further propagating the oxidative burden on the microvasculature. This study did not probe the causative link between MDD and increased vascular oxidative stress, which is a limitation. Relatively few studies have examined the specific mechanism(s) by which MDD results in increased NADPH oxidase expression and activity. Angiotensin II is a potent stimulator of NADPH oxidase, 48 and, importantly, dysregulation of angiotensin II signaling has been described in depression. 56 Treatment with an angiotensin II receptor antagonist reduces oxidative stress and exerts antidepressant-like effects in rodent models. 57 In humans, most studies suggest that drugs targeting the renin-angiotensin-aldosterone system improve depressive symptoms. 58 MDD-induced alterations in the renin-angiotensin-aldosterone system may trigger excessive activation of vascular NADPH oxidase having deleterious consequences for endothelial function. Further, there is strong and broad support for the general hypothesis that inflammation plays a critical role in the pathogenesis of MDD, at least in some individuals. 59 Inflammatory cytokines, in turn, regulate vascular NADPH oxidases, linking inflammation to oxidative stress. The potential for angiotensin II or inflammatory cytokines to contribute an upregulation of NADPH oxidase in MDD remains to be examined.
Our data also demonstrate significant impairments in SNP-induced endothelium-independent dilation in MDD, suggesting a loss of sensitivity to NO in the VSMC itself also contributes to the marked microvascular dysfunction in MDD. This finding was unexpected given the preservation of (1) SNP-induced dilation documented in rodent models 18, 19 and (2) nitroglycerin-induced brachial artery dilation in adults with MDD. 8, 11 However, ROS, particularly NADPH oxidasederived superoxide, play a major role in VSMC tone, particularly in the microcirculation. 60 Thus, given that alterations in microvascular function are evident before impairments in large conduit arteries, it is conceivable that our approach allowed us to detect early MDD-related impairments in the ability of the VSMC to respond to NO before similar functional deficits can be observed in other vascular beds. However, in the present study design, it is not possible to determine the extent to which impairments in endothelial or VSMC function in isolation-or in combination-contribute to the microvascular dysfunction evident in MDD.
Young women are more than twice as likely to develop MDD as men and also suffer greater depressive symptom severity. 23 However, premenopausal women have lower CVD risk than men, despite the presence of comparable risk factors, including depression, 22 thus implicating sex differences in the pathophysiology underlying the MDD-CVD link. In preclinical models, investigators have demonstrated a greater susceptibility to depressive symptoms but less severe impairments in endothelial function in female compared with male rodents. 17, 19, 45 This relative preservation of endothelial function in female rodents has been attributed to greater antioxidant defense mechanisms and subsequent maintenance of NO bioavailability and function. 19 However, to date, no studies have examined sex differences in the mechanisms underlying vascular dysfunction in otherwise healthy young adults with MDD.
In contrast to our hypothesis, there were no sex differences in ACh-induced dilation alone or during concurrent NOS February 15, 2019 inhibition in adults with MDD. Further, there were no sex differences in SNP-induced dilation. These data suggest that sex does not substantially modulate the relative contribution of NO to vasodilatory mechanisms in the microvasculature in MDD. It is important to note that the young women in the present study were studied without regard for menstrual cycle phase or oral contraceptive use. Recent studies suggest that endothelial function is stable across the menstrual and hormonal contraceptive cycles. 61, 62 Changes in female sex hormones do not appear to influence ACh-induced dilation in the cutaneous microcirculation. 62, 63 In addition, rodent models of depression demonstrate that endothelial dysfunction is apparent throughout the estrous cycle, despite a varied hormonal profile. 19 Because a detailed examination of the influence of cyclic variation in estrogen on endothelial function was not the primary purpose of this study, we instead probed for a true sex difference in NO-mediated vascular function. Further, because MDD adults were nonmedicated, experimental visits were scheduled immediately after enrollment, and investigators encouraged all MDD patients to expediently seek clinical follow-up.
We acknowledge that the MDD adults in the present study presented a limited range of depressive symptom severity and recognize that this sample reflects only part of the spectrum of MDD and, therefore, may not be representative of more severely ill patients or patients with additional psychiatric and medical comorbidities. Nevertheless, we detected marked impairments in NO-mediated microvascular function in this MDD cohort, which are comparable in magnitude to the deficits reported in adults with traditional CVD risk factors. 34, 64, 65 Future studies are required to determine the potential relation between depressive symptom severity and the mechanistic mediators of endothelial dysfunction in MDD.
In this study, microvascular function was assessed in adults with MDD during a current depressive episode, limiting our ability to make inferences regarding the temporal relation between depressive symptom development and microvascular dysfunction. In a recent meta-analysis, 13 the majority of included studies reported a significant inverse relation between depression and endothelial function, regardless of whether of depression was current or remitted. Although a prospective longitudinal study conducted during the course of several years in adults with MDD could better address the temporal relation between symptomology and microvascular dysfunction, the inability to predict depressive episode onset and remission makes the logistics of these types of studies challenging. In an effort to begin to address this question, we assessed endothelium-dependent and endothelium-independent dilation in a cohort of adults with MDD currently treated with an SSRI to manage their depressive symptoms and in remission. Consistent with previous reports in both rodents and humans, [31] [32] [33] 46 the NO-mediated component of endotheliumdependent dilation was improved in SSRI-treated adults. In contrast, endothelium-independent dilation was impaired to a similar magnitude in SSRI-treated adults and MDD adults in a current depressive episode. Although these data are inherently limited by their cross-sectional nature, as well as by the potential for SSRI treatment to directly influence vascular function independent of improvements in symptoms, 66 they represent a critical first step in designing future prospective studies to more specifically test research questions pertaining to the temporal association between depressive mood and endothelial dysfunction, as well as determining the mechanistic mediators of this relation.
Lastly, depression is comorbid with many cardiovascular risk factors (eg, aging, tobacco use, obesity, and physical inactivity), and it is now evident that this relation is bidirectional. 6 Over time, the added presence of any of these behavioral or physiological factors in adults with MDD would likely only exacerbate the severity of microvascular dysfunction, thereby further accelerating the atherosclerotic disease process. By study design, every attempt was made to limit these additional risk factors in the present study, in an effort to isolate the influence of MDD itself on microvascular function. However, consideration of these additional risk factors will be critical for future prospective studies designed to better understand the mechanistic link between psychological and physiological function.
Perspectives and Conclusions
These findings demonstrate that increased oxidative stress, via reductions in NO-dependent mechanisms, directly contributes to microvascular dysfunction in otherwise healthy young adults with MDD. Additionally, sex does not appear to selectively modulate NO-dependent dilatory mechanisms in depression. Collectively, these findings establish the experimental basis for conducting interventional studies targeting vascular oxidative stress as a means to improve vascular function and reduce CVD risk in adults with clinical depression. Interestingly, strategies targeting oxidative stress in the microvasculature may also have therapeutic and preventative effects on the pathogenesis of depression itself. In this regard, the vascular depression hypothesis posits that cerebrovascular disease may predispose, precipitate, or perpetuate some depressive symptoms in the elderly. 67 Based on this hypothesis, it is tempting to speculate that microvascular endothelial dysfunction, particularly in the cerebral microcirculation, could conceivably contribute to the development of depressive symptoms in otherwise healthy young adults via its effects on structural and functional neurocircuitry. This conjecture, which is supported by evidence linking inflammation-in part, via oxidative stress-to the neurobiology of depression, 59 represents an exciting venue for continued research.
